RGEN|Repligen Corp|Price:142.180|Chg%:2.52

More Details of Repligen Corp Company

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.

Repligen Corp Info



Ticker SymbolRGEN

Company nameRepligen Corp

IPO dateApr 29, 1986

CEOLoeillot (Olivier)

Number of employees1778

Security typeOrdinary Share

Fiscal year-endApr 29

AddressBuilding 1, Suite 100

CityWALTHAM

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryUnited States of America

Postal code02453

Phone17814499560

Websitehttps://www.repligen.com/

Ticker SymbolRGEN

IPO dateApr 29, 1986

CEOLoeillot (Olivier)

Company Executives of Repligen Corp



Name

Name/Position

Position

Shareholding

Change

Ms. Karen A. Dawes

Lead Independent Director

91.02K

-275.00%

Mr. Glenn P. Muir

Independent Director

35.92K

+3366.00%

Mr. Ralf Kuriyel

Senior Vice President - Research and Development

12.56K

+7478.00%

Mr. Olivier Loeillot

President, Chief Executive Officer, Director

6.02K

-7041.00%

Mr. Nicolas M. Barthelemy

Independent Director

4.94K

+973.00%

Mr. Rohin Mhatre, Ph.D.

Independent Director

3.32K

+973.00%

Mr. Tony John Hunt

Executive Chairman of the Board

--

Ms. Carrie Eglinton Manner

Independent Director

--

Mr. James R. Bylund

Chief Operating Officer

--

Dr. Konstantin Konstantinov, Ph.D.

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Ms. Karen A. Dawes

Lead Independent Director

91.02K

-275.00%

Mr. Glenn P. Muir

Independent Director

35.92K

+3366.00%

Mr. Ralf Kuriyel

Senior Vice President - Research and Development

12.56K

+7478.00%

Mr. Olivier Loeillot

President, Chief Executive Officer, Director

6.02K

-7041.00%

Mr. Nicolas M. Barthelemy

Independent Director

4.94K

+973.00%

Mr. Rohin Mhatre, Ph.D.

Independent Director

3.32K

+973.00%

Revenue Breakdown

Currency: USDUpdated: Tue, Jan 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Relevant data have not been disclosed by the company yet.

By RegionUSD

Name

Revenue

Proportion

North America

96.29M

51.00%

Europe

56.64M

30.00%

APAC/Other

35.87M

19.00%

By Business

By Region

Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Mon, Dec 8

Shareholders

Shareholder Types

Shareholders

Proportion

The Vanguard Group, Inc.

8.85%

BlackRock Institutional Trust Company, N.A.

8.24%

T. Rowe Price Associates, Inc.

6.14%

Roy T. Eddleman UEO

5.88%

United Capital Financial Advisors, LLC

4.90%

Other

65.99%

Shareholders

Proportion

The Vanguard Group, Inc.

8.85%

BlackRock Institutional Trust Company, N.A.

8.24%

T. Rowe Price Associates, Inc.

6.14%

Roy T. Eddleman UEO

5.88%

United Capital Financial Advisors, LLC

4.90%

Other

65.99%

Shareholder Types

Shareholders

Proportion

Investment Advisor

60.03%

Investment Advisor/Hedge Fund

30.39%

Hedge Fund

15.72%

Individual Investor

6.35%

Research Firm

2.20%

Pension Fund

1.95%

Bank and Trust

1.82%

Sovereign Wealth Fund

0.60%

Family Office

0.50%

Institutional Shareholding



Updated: Thu, Jan 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q4

1044

63.74M

113.23%

+2.55M

2025Q3

1027

55.23M

98.12%

-6.26M

2025Q2

1028

61.98M

110.32%

-3.21M

2025Q1

1054

62.91M

111.98%

-2.72M

2024Q4

1054

61.13M

109.11%

-3.76M

2024Q3

1046

60.75M

108.48%

-6.10M

2024Q2

1039

61.28M

109.67%

-2.73M

2024Q1

1036

60.56M

108.45%

-5.41M

2023Q4

1062

62.13M

111.29%

-2.30M

2023Q3

1063

61.47M

110.27%

+2.91M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

5.03M

8.94%

-33.74K

-0.67%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

4.64M

8.24%

-70.77K

-1.50%

Sep 30, 2025

T. Rowe Price Associates, Inc.

3.46M

6.14%

+27.66K

+0.81%

Sep 30, 2025

Roy T. Eddleman UEO

3.31M

5.88%

-67.50K

-2.00%

Dec 31, 2024

United Capital Financial Advisors, LLC

2.76M

4.9%

+2.76M

--

Sep 30, 2025

Fidelity Management & Research Company LLC

2.29M

4.08%

+930.01K

+68.16%

Sep 30, 2025

State Street Investment Management (US)

1.80M

3.2%

+178.91K

+11.03%

Sep 30, 2025

Citadel Advisors LLC

1.68M

2.99%

+621.66K

+58.48%

Sep 30, 2025

Point72 Asset Management, L.P.

1.44M

2.56%

-472.47K

-24.70%

Sep 30, 2025

Holocene Advisors, LP

1.38M

2.45%

+440.29K

+47.00%

Sep 30, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

First Trust NYSE Arca Biotechnology Index Fund

3.45%

Alger Mid Cap 40 ETF

3.1%

Congress SMid Growth ETF

2.46%

iShares Health Innovation Active ETF

2.28%

VanEck Biotech ETF

1.34%

Franklin Genomic Advancements ETF

1.23%

Pacer US Export Leaders ETF

1.18%

Alger 35 ETF

1.15%

WisdomTree BioRevolution Fund

1.06%

iShares Biotechnology ETF

0.7%

First Trust NYSE Arca Biotechnology Index Fund

Proportion3.45%

Alger Mid Cap 40 ETF

Proportion3.1%

Congress SMid Growth ETF

Proportion2.46%

iShares Health Innovation Active ETF

Proportion2.28%

VanEck Biotech ETF

Proportion1.34%

Franklin Genomic Advancements ETF

Proportion1.23%

Pacer US Export Leaders ETF

Proportion1.18%

Alger 35 ETF

Proportion1.15%

WisdomTree BioRevolution Fund

Proportion1.06%

iShares Biotechnology ETF

Proportion0.7%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

No Data

Date

Ex-dividend Date

Type

Ratio

No Data